Press

Numinus to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

Jun 9 • 2 min read

Numinus Wellness Inc. (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will present at the Healthcare Virtual Conference presented by Maxim Group LLC and hosted by M-Vest, on June 20-22, 2023. Payton Nyquvest, Founder and CEO of Numinus, will participate in a Mental Health Care Clinics panel discussion…

BetterLife Continues Progress on BETR-001 IND-Enabling Studies

Jun 9 • 3 min read

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that the IND-enabling studies BetterLife’s 2-bromo-LSD (“BETR-001”) continue to progress. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (“LSD”) derivative molecule. BetterLife has previously completed the preclinical pharmacological profiling of BETR-001, which showed…

Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)

Jun 7 • 4 min read

Enveric Biosciences, Inc. (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that its research involving the synthesis of small molecule derivatives of psychoactive compounds has been featured in two poster presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)…

PSYC’s Psychedelic Spotlight Continues Ascent as a Top-Ranking Multimedia Platform for the Psychedelics Sector

Jun 7 • 5 min read

PSYC Corporation (OTC Pink Market: PSYC), parent company to Spotlight Media Corporation (“SMC” or the “wholly owned subsidiary”), a multimedia leader for all things psychedelics including the emerging medicinal psychedelics market sector, is pleased to announce that its 100% owned and operated multimedia platform, Psychedelic Spotlight, reported another statistical record setting month in May which, according to the…

COMPASS Pathways’ key patents upheld by the US Patent and Trademark Office

Jun 7 • 2 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation, announced today that the US Patent Trial and Appeal Board (PTAB) reaffirmed decisions to uphold ‘257 Patent and ‘259 Patent, key patents covering COMP360 crystalline psilocybin polymorph A, the polymorph being used in the Company’s phase 3…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441